Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics has announced a partnership with Cell Therapies Pty Ltd to potentially manufacture its innovative CAR T cell therapies in Australia, aiming to provide Australian cancer patients with access to ground-breaking clinical trials. This collaboration leverages Cell Therapies’ unique capability to produce ‘living’ cancer therapies at a commercial scale in Australia. Chimeric is currently advancing a diversified portfolio in oncology with four clinical stage programs, including trials for gastrointestinal, neuroendocrine tumours, and glioblastoma.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
